The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of beta-catenin. The disclosure also relates to applications in the treatment of ophthalmic conditions, such as macular degeneration and glaucoma, and pharmaceutical compositions comprising such alpha helix mimetic beta-catenin inhibitors.
